January 6, 2023
Share our DTE comment letter with your BOPs
APC recently submitted a comment letter on DTE to the FDA docket outlining our concerns with the recent reclassification of DTE.
We ask you to please share this letter with your boards of pharmacy members and director in an effort to assure continued patient access to compounded thyroid medications. It includes a summary memo that may aid you in your communications.